Personalized_Medicine_A_New_Medical_and_Social_Challenge
determinants, such as model specifications, data used, or different exogenous factors. Therefore, the ICER can be seen as a poin ...
UK, Australia also developed its national framework for assessing personalized medicine products for the purpose of assisting re ...
piece of information for a reimbursement decision is knowing whether the bio- marker is a treatment effect modifier or a prognos ...
report, the concern for cost inflation fueled by personalized medicine seems justi- fied. This has already been acknowledged. Fo ...
A more recent study by Johnson et al. ( 2015 ) reported important financial benefits stemming from the use of genotype-guided an ...
4 Methodological Challenges for Economic Evaluations of Companion Diagnostics Typical economic evaluation requires averaged data ...
the diagnostic technology. In some cases, cost-effectiveness studies may not even be necessary due to very small prevalence of a ...
established the Harvard-Partners Center for Genetics and Genomics (HPCGG),^35 aiming to move genetics and genomics into clinical ...
4.2 Available Evidence Personalized medicine is a data-driven approach, and a critical step in the devel- opment of personalized ...
both analysts and policy makers should be realistic about their expectations relating to the quality and quantity of data that i ...
however, collecting this new and complex evidence, especially in the preapproval phase of the technology’s development, is provi ...
the current reimbursement systems for diagnostic tests (whether single or compan- ion tests) are cost based rather than value ba ...
value of a health outcome that, at least in theory, can encompass all aspects of a health improvement. Patients can benefit from ...
properly defined.^49 Analysis of the social value of innovative technologies will enable proper assessment of social costs, answ ...
5 Concluding Remarks Ma and Lu ( 2011 ) suggest that the goal of personalized medicine is for physicians to prescribe an appropr ...
the test result and treatment choice may sometimes be weak, at best. For instance, a genetic test may identify patients at risk ...
Bobinac A, van Exel NJA, Rutten FFH, Brouwer WBF (2013) Valuing QALY gains by applying a societal perspective. Health Econ 22(10 ...
Freidlin B, McShane LM, Korn EL (2010) Randomized clinical trials with biomarkers: design issues. J Natl Cancer Inst 102:152–160 ...
Neumann PJ, Greenberg D (2009) Is the United States ready for QALYs? Health Aff 28:1366–1371 Neumann PJ, Cohen JT, Hammitt JK, C ...
Computational Methods for Integration of Biological Data Vladimir Gligorijevic ́and NatasˇaPržulj Abstract As we keep accumulati ...
«
2
3
4
5
6
7
8
9
10
11
»
Free download pdf